255 related articles for article (PubMed ID: 3162051)
41. Circulating hepatocyte growth factor as an independent prognostic factor of disseminated intravascular coagulation.
Chung S; Kim JE; Kim JY; Lee DS; Han KS; Kim HK
Thromb Res; 2010 Jun; 125(6):e285-93. PubMed ID: 20185166
[TBL] [Abstract][Full Text] [Related]
42. Diphasic increase in thrombin-antithrombin III complex in blood from the internal jugular vein following severe head injury.
Suzuki M; Motohashi O; Nishino A; Shiina V; Mizoi K; Yoshimoto T; Kameyama M; Onuma T
Thromb Haemost; 1994 Jan; 71(1):155-7. PubMed ID: 8165638
[No Abstract] [Full Text] [Related]
43. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Booth NA; Bennett B
Br J Haematol; 1984 Apr; 56(4):545-56. PubMed ID: 6201189
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the coagulation and fibrinolytic systems in men with intermittent claudication.
Handa K; Takao M; Nomoto J; Oku K; Shirai K; Saku K; Arakawa K
Angiology; 1996 Jun; 47(6):543-8. PubMed ID: 8678328
[TBL] [Abstract][Full Text] [Related]
45. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
Wada H; Sakuragawa N; Mori Y; Takagi M; Nakasaki T; Shimura M; Hiyoyama K; Nisikawa M; Gabazza EC; Deguchi K; Kazama M; Shiku H
Am J Hematol; 1999 Apr; 60(4):273-8. PubMed ID: 10203100
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of antithrombin III, plasminogen and alpha 2-plasmin inhibitor in perinatal period.
Fuse Y; Fuse K
Asia Oceania J Obstet Gynaecol; 1985 Mar; 11(1):121-5. PubMed ID: 3160323
[No Abstract] [Full Text] [Related]
47. [Clinical evaluation of alpha 2 plasmin inhibitor and alpha 2 plasmin inhibitor-plasmin complex by enzyme immunoassay method--with special reference to accident surgery].
Fukuda C; Iijima K; Inoue N; Takashima Y; Urabe C; Nakamura K
Rinsho Byori; 1988 Mar; 36(3):346-50. PubMed ID: 2969986
[No Abstract] [Full Text] [Related]
48. [alpha 2-Plasmin inhibitor-plasmin complex (PIC)].
Yoshikawa Y; Sakata Y
Nihon Rinsho; 1995 Mar; 53 Su Pt 2():55-8. PubMed ID: 8753179
[No Abstract] [Full Text] [Related]
49. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. colisepsis--toward a distinction between uncompensated overt DIC and compensated non-overt DIC.
Wada H; Yamamuro M; Inoue A; Shiku H; Sakuragawa N; Redl H; Peer G; Taylor FB
Thromb Haemost; 2001 Dec; 86(6):1489-94. PubMed ID: 11776318
[TBL] [Abstract][Full Text] [Related]
51. [Plasma levels of antithrombin III, thrombin-antithrombin III complex, alpha 2 plasmin inhibitor and plasmin alpha 2 plasmin inhibitor complex in normal and sick newborn infants].
Shiiki M; Ariyoshi N; Nakamura T; Shirahata A
Rinsho Ketsueki; 1991 Jul; 32(7):758-65. PubMed ID: 1833569
[TBL] [Abstract][Full Text] [Related]
52. Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3.
Bemelman FJ; Buysmann S; Wilmink JM; Surachno S; Hack CE; Schellekens PT; ten Berge RJ
Transplant Proc; 1994 Dec; 26(6):3096-7. PubMed ID: 7527944
[No Abstract] [Full Text] [Related]
53. [Automation of colorimetry using chromogenic substrates, with special reference to blood coagulation disorders in acute myelocytic leukemia].
Hashizume K; Tanaki T; Horita H; Yoshitani H; Kumatani Y; Matsuda T; Ito K
Rinsho Byori; 1985 Feb; Spec No 61():114-8. PubMed ID: 3858561
[No Abstract] [Full Text] [Related]
54. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group.
Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Mori Y; Shiku H
Thromb Haemost; 1995 Sep; 74(3):848-52. PubMed ID: 8571309
[TBL] [Abstract][Full Text] [Related]
55. [Significance of factors of coagulation and fibrinolysis in progression of lung cancer].
Nagayama M; Tachibana A; Hayakawa H; Sato A
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Feb; 31(2):180-5. PubMed ID: 8390588
[TBL] [Abstract][Full Text] [Related]
56. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
57. Change of lipoprotein(a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy.
Nagai T; Tomizawa T; Mori M
Diabetes Care; 1993 Oct; 16(10):1411-2. PubMed ID: 8269808
[No Abstract] [Full Text] [Related]
58. [New clinical tests in diagnosis of hematologic diseases].
Nakahara K
Nihon Naika Gakkai Zasshi; 1993 Apr; 82(4):529-33. PubMed ID: 8340662
[No Abstract] [Full Text] [Related]
59. Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Koyama T; Kakishita E; Nakai Y; Okamoto E
Am J Hematol; 1991 Oct; 38(2):90-4. PubMed ID: 1719808
[TBL] [Abstract][Full Text] [Related]
60. Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.
Handa K; Kimoto K; Kawaguchi H; Mori T; Matsunaga A; Sasaki J; Arakawa K
Int J Cardiol; 1993 Dec; 42(3):263-7. PubMed ID: 7511130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
